Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2003 2
2004 1
2005 2
2006 1
2007 2
2009 1
2010 1
2013 2
2014 1
2015 3
2016 11
2017 8
2018 6
2019 7
2020 7
2021 12
2022 13
2023 3
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.
Østergaard M, van Vollenhoven RF, Rudin A, Hetland ML, Heiberg MS, Nordström DC, Nurmohamed MT, Gudbjornsson B, Ørnbjerg LM, Bøyesen P, Lend K, Hørslev-Petersen K, Uhlig T, Sokka T, Grondal G, Krabbe S, Lindqvist J, Gjertsson I, Glinatsi D, Kapetanovic MC, Aga AB, Faustini F, Parmanne P, Lorenzen T, Giovanni C, Back J, Hendricks O, Vedder D, Rannio T, Grenholm E, Ljoså MK, Brodin E, Lindegaard H, Söderbergh A, Rizk M, Kastbom A, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Bay Laurbjerg T, Bakland G, Olsen IC, Haavardsholm EA, Lampa J; NORD-STAR study group. Østergaard M, et al. Among authors: hendricks o. Ann Rheum Dis. 2023 Oct;82(10):1286-1295. doi: 10.1136/ard-2023-224116. Epub 2023 Jul 9. Ann Rheum Dis. 2023. PMID: 37423647 Clinical Trial.
Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset.
Saevarsdottir S, Stefansdottir L, Sulem P, Thorleifsson G, Ferkingstad E, Rutsdottir G, Glintborg B, Westerlind H, Grondal G, Loft IC, Sorensen SB, Lie BA, Brink M, Ärlestig L, Arnthorsson AO, Baecklund E, Banasik K, Bank S, Bjorkman LI, Ellingsen T, Erikstrup C, Frei O, Gjertsson I, Gudbjartsson DF, Gudjonsson SA, Halldorsson GH, Hendricks O, Hillert J, Hogdall E, Jacobsen S, Jensen DV, Jonsson H, Kastbom A, Kockum I, Kristensen S, Kristjansdottir H, Larsen MH, Linauskas A, Hauge EM, Loft AG, Ludviksson BR, Lund SH, Markusson T, Masson G, Melsted P, Moore KHS, Munk H, Nielsen KR, Norddahl GL, Oddsson A, Olafsdottir TA, Olason PI, Olsson T, Ostrowski SR, Hørslev-Petersen K, Rognvaldsson S, Sanner H, Silberberg GN, Stefansson H, Sørensen E, Sørensen IJ, Turesson C, Bergman T, Alfredsson L, Kvien TK, Brunak S, Steinsson K, Andersen V, Andreassen OA, Rantapää-Dahlqvist S, Hetland ML, Klareskog L, Askling J, Padyukov L, Pedersen OB, Thorsteinsdottir U, Jonsdottir I, Stefansson K; Members of the DBDS Genomic Consortium; Danish RA Genetics Working Group; Swedish Rheumatology Quality Register Biobank Study Group (SRQb). Saevarsdottir S, et al. Among authors: hendricks o. Ann Rheum Dis. 2022 Aug;81(8):1085-1095. doi: 10.1136/annrheumdis-2021-221754. Epub 2022 Apr 25. Ann Rheum Dis. 2022. PMID: 35470158 Free PMC article.
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
Hetland ML, Haavardsholm EA, Rudin A, Nordström D, Nurmohamed M, Gudbjornsson B, Lampa J, Hørslev-Petersen K, Uhlig T, Grondal G, Østergaard M, Heiberg MS, Twisk J, Lend K, Krabbe S, Hyldstrup LH, Lindqvist J, Hultgård Ekwall AK, Grøn KL, Kapetanovic M, Faustini F, Tuompo R, Lorenzen T, Cagnotto G, Baecklund E, Hendricks O, Vedder D, Sokka-Isler T, Husmark T, Ljoså MA, Brodin E, Ellingsen T, Söderbergh A, Rizk M, Olsson ÅR, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Laurberg TB, Bakland G, Olsen IC, van Vollenhoven R; NORD-STAR study group. Hetland ML, et al. Among authors: hendricks o. BMJ. 2020 Dec 2;371:m4328. doi: 10.1136/bmj.m4328. BMJ. 2020. PMID: 33268527 Free PMC article. Clinical Trial.
The role of antirheumatics in patients with COVID-19.
Nissen CB, Sciascia S, de Andrade D, Atsumi T, Bruce IN, Cron RQ, Hendricks O, Roccatello D, Stach K, Trunfio M, Vinet É, Schreiber K. Nissen CB, et al. Among authors: hendricks o. Lancet Rheumatol. 2021 Jun;3(6):e447-e459. doi: 10.1016/S2665-9913(21)00062-X. Epub 2021 Mar 30. Lancet Rheumatol. 2021. PMID: 33817665 Free PMC article. Review.
Women with gout and COVID-19-an unfortunate combination?
Nissen CB, Hendricks O, Schreiber K. Nissen CB, et al. Among authors: hendricks o. Lancet Rheumatol. 2022 Apr;4(4):e233-e234. doi: 10.1016/S2665-9913(22)00026-1. Epub 2022 Jan 28. Lancet Rheumatol. 2022. PMID: 35128469 Free PMC article. No abstract available.
Reversal of resistance in microorganisms by help of non-antibiotics.
Kristiansen JE, Hendricks O, Delvin T, Butterworth TS, Aagaard L, Christensen JB, Flores VC, Keyzer H. Kristiansen JE, et al. Among authors: hendricks o. J Antimicrob Chemother. 2007 Jun;59(6):1271-9. doi: 10.1093/jac/dkm071. Epub 2007 Apr 2. J Antimicrob Chemother. 2007. PMID: 17403708 Review.
Long-term efficacy of a 2-year MRI treat-to-target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission: 5-year follow-up of the IMAGINE-RA randomised trial.
Møller-Bisgaard S, Hørslev-Petersen K, Ørnbjerg LM, Ejbjerg B, Hetland ML, Møller JM, Nielsen SM, Glinatsi D, Boesen M, Stengaard-Pedersen K, Madsen OR, Jensen B, Villadsen JA, Hauge EM, Hendricks O, Lindegaard H, Krogh NS, Jurik AG, Thomsen H, Christensen R, Østergaard M. Møller-Bisgaard S, et al. Among authors: hendricks o. RMD Open. 2024 Mar 15;10(1):e003945. doi: 10.1136/rmdopen-2023-003945. RMD Open. 2024. PMID: 38490697 Free PMC article. Clinical Trial.
73 results